Humana · Tumor Genomic Profiling · US health-plan appeal rights

Tumor Genomic Profiling denied for failing step therapy by Humana?

Q: How long do I have to appeal a Humana Tumor Genomic Profiling denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

Step-therapy denials usually flip when the appeal documents that prior alternatives were tried and failed, or were contraindicated, or aren't safe for the patient.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-11

Policy data current as of 2026-04-26

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Humana typically requires

Humana's specific coverage criteria for tumor genomic profiling are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

Source policy: Humana Genetic Testing (eviCore for commercial + MA); MA follows CMS NCDs/LCDs

The Humana angle on Tumor Genomic Profiling

## Why Humana Denied Tumor Genomic Profiling Under Step Therapy

A step-therapy denial for tumor genomic profiling means Humana's policy requires that one or more prerequisite clinical steps be completed — and documented — before comprehensive genomic profiling is covered. In the oncology context this typically means that a simpler or more targeted test must be attempted first, or that certain prior-line treatments must have been tried and failed before broader genomic profiling is approved. This "fail-first" framework is common in drug coverage but less intuitive when applied to diagnostics.

This denial is frequently appealable, particularly in oncology. Major guidelines — including applicable NCCN recommendations — often support comprehensive genomic profiling at specific cancer types and stages without requiring a step-through of lower-complexity testing, because the comprehensive results inform a broader set of treatment decisions simultaneously. If Humana's step requirement conflicts with guideline-supported care, that gap is the foundation of the appeal.

## Federal Appeal Framework

Under ACA Section 2719, step-therapy denials are subject to full internal appeal and independent external review. Many states also have enacted step-therapy override laws that provide additional patient protections, which may apply depending on whether your plan is state-regulated or ERISA-governed. File your internal appeal within 180 days of the denial notice. External review is available within approximately 4 months of the final internal denial. Expedited review is available when delay would adversely affect your health or treatment timeline. ERISA plans carry equivalent rights under Section 503.

## Concrete Appeal Steps

1. Obtain Humana's step-therapy criteria for tumor genomic profiling — identify exactly which prior steps are required. 2. Determine whether any required prior steps have already been completed; if so, document them with dates and results. 3. If prior steps are clinically inappropriate or contraindicated for your situation, have your oncologist document that specifically. 4. Build an appeal demonstrating either (a) step completion or (b) clinical exception justifying step bypass. 5. Reference applicable guideline support for direct comprehensive profiling.

## Documentation to Gather

Step-completion records: If any required prior tests or treatments have been completed, include reports with dates and outcomes.
Clinical exception documentation: If required prior steps are not clinically appropriate (e.g., a simpler test cannot answer the clinical question for your cancer type), oncologist letter explaining why.
Diagnosis and staging: Pathology, cancer type, stage, and current disease status.
Guideline support: Applicable NCCN or equivalent guideline supporting direct comprehensive genomic profiling for your cancer type — oncologist confirms your case meets criteria.
Medical-necessity letter: Oncologist letter addressing each step-therapy requirement and explaining why comprehensive profiling is needed now.

## Criteria-Mapping Structure

List each step in Humana's step-therapy protocol. For each step: either document completion (with date and result) or provide oncologist attestation of a clinical exception reason. A step-by-step accounting — rather than a general medical-necessity argument — is the most effective structure for overcoming a step-therapy denial.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Humana appeals

Other insurers on Tumor Genomic Profiling

Other denial reasons for Humana Tumor Genomic Profiling

denied as not medically necessary denied as non-formulary denied for missing prior authorization denied as experimental or investigational denied as not FDA-approved for this use

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-11. Editorial standards: denialhelp.com/authors.